Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122591) titled 'An exploratory clinical study on the efficacy and safety of irinotecan liposome injection combined with tislelizumab in the treatment of small cell lung cancer' on April 15.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Affiliated Hospital of Guangdong Medical University

Condition: small cell lung cancer

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-04-16

Target Sample Size: Experimental group:30;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=315528

Published by HT Digital Content Services...